正清风痛宁片联合塞来昔布对类风湿关节炎患者疾病活动指标、炎症因子及红细胞免疫功能的影响

Effect of Zhengqingfengtongning Tablet Combined with Celecoxib on Disease Activity Indexes, Inflammatory Factors and Red Blood Cell Immune Function in Patients with Rheumatoid Arthritis

目的:探讨正清风痛宁片联合塞来昔布对类风湿关节炎(RA)患者疾病活动指标、炎症因子及红细胞免疫功能的影响。方法:选取2016年8月~2019年10月我院接收的117例RA患者。根据随机数字表法分为研究组(n=59)、对照组(n=58)。对照组予以塞来昔布治疗,研究组在对照组的基础上联合正清风痛宁片治疗,两组均治疗1个月。统计两组治疗1个月后的临床疗效。比较两组治疗前、治疗1个月后的疾病活动指标[类风湿因子(RF)、C反应蛋白(CRP)、血沉(ESR)],红细胞免疫功能指标CR1、CD59以及炎症因子指标[肿瘤坏死因子-α(TNF-α)、白介素-1β(IL-1β)以及白介素-6(IL-6)],记录两组治疗期间不良反应情况。结果:研究组治疗1个月后的总有效率为89.83%(53/59),高于对照组的72.41%(42/58)(P<0.05)。两组不良反应发生率对比无差异(P>0.05)。两组治疗1个月后RF、CRP、ESR、TNF-α、IL-1β以及IL-6水平均较治疗前下降,且研究组低于对照组(P<0.05)。两组治疗1个月后CR1、CD59均较治疗前升高,且研究组高于对照组(P<0.05)。结论:正清风痛宁片联合塞来昔布治疗RA患者,疗效显著,可有效降低患者疾病活动指标、炎症因子水平,提高红细胞免疫功能,且不增加不良反应发生率。

Objective: To investigate the effect of Zhengqingfengtongning tablet combined with celecoxib on disease activity index, inflammatory factors and red blood cell immune function in patients with rheumatoid arthritis(RA). Methods: 117 patients with RA who were admitted to our hospital from August 2016 to October 2019 were selected. The patients were randomly divided into control group(n=58) and study group(n=59) by random number table method. The control group was treated with celecoxib, and the study group was treated with Zhengqingfengtongning tablet on the basis of the control group. Both groups were treated for 1 month. The clinical effect of the two groups at 1 month after treatment was statisticed. Disease activity indexes [rheumatoid factor(RF), C-reactive protein(CRP), erythrocyte(ESR)], red blood cell immune function indexes CR1, CD59, and inflammatory factors [tumor necrosis factor-α(TNF-α), interleukin-1β(IL-1β) and interleukin-6(IL-6)] were compared between the two groups before treatment and 1 month after treatment, and the adverse reactions during treatment were recorded. Results: The total effective rate of the study group after one month was 89.83%(53/59), which was higher than 72.41%(42/58) of the control group(P<0.05). There was no statistically significant difference in the incidence rate of adverse reactions between the two groups(P>0.05). 1 month after treatment, RF, CRP, ESR, TNF-α, IL-1βand IL-6 levels in both groups decreased compared with those before treatment, and the study group was lower than the control group(P<0.05). 1 month after treatment, CR1 and CD59 in both groups were increased compared with those before treatment, and the study group was higher than the control group(P<0.05). Conclusion: Zhengqingfengtongning tablet combined with celecoxib in the treatment of patients with RA has a significant effect, which can effectively reduce disease activity indexes and inflammatory factors in patients,improve the red blood cell immune function, and which do not increase the incidence of adverse reactions.